박용욱 교수 연구실
article|
gold
·인용수 1
·2025
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, Young Rong Kim, Jin Soo Lee, Dong Sik Jung, Shin‐Woo Kim, Kyung Hwa Park, Joong Sik Eom, Su Jin Jeong, Jacob Lee, Ki Tae Kwon, Hee Jung Choi, Jang Wook Sohn, Young Keun Kim, Yoonyeong Lee, Ho Keun Park, Ji Hwa Ryu, Su Jeen Lee, Yong Wook Park, Hun Kim, Francesca Solmi, Maria Angeles Ceregido, Marguerite Koutsoukos, Neil P. King, David Veesler, Hee Jin Cheong
International Journal of Infectious Diseases
초록
A homologous GBP510/AS03 booster was well tolerated and induced robust, durable neutralizing antibody responses against SARS-CoV-2, including Omicron variant.
키워드
ImmunogenicityHomologous chromosomeRecombinant DNABooster doseBooster (rocketry)Neutralizing antibody